Bristol-Myers Squibb Co (LTS:0R1F)
$ 59.4 -0.61 (-1.02%) Market Cap: 119.70 Bil Enterprise Value: 163.01 Bil PE Ratio: 0 PB Ratio: 6.98 GF Score: 82/100

Bristol-Myers Squibb Co at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 12:10PM GMT
Release Date Price: $75.62 (+8.39%)
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

Great. Good morning, everybody. Thanks for joining us today. I'm Terence Flynn, the pharma analyst at Morgan Stanley. Just first on disclosures. For important disclosures, please see the Morgan Stanley research website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

This morning, I'm very pleased to be hosting Bristol-Myers. Today from the company, we have Chris Boerner, who is Executive Vice President and Chief Commercial Officer. Thanks for joining us, Chris.

Christopher S. Boerner
Bristol-Myers Squibb Company - Executive VP & Chief Commercialization Officer

Happy to be here.

Questions & Answers

Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

So before I get into the congratulations on deucrava or SOTYKTU, which we are just

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot